{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:30:59Z","timestamp":1786113059080,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>To investigate the clinical features, management strategies, and prognosis of the rare condition of upper tract urothelial carcinoma (UTUC) with skin metastasis, with emphasis on the efficacy and safety of disitamab vedotin combined with tislelizumab in systemic therapy, we performed a literature search and selection. We searched PubMed, Embase, and Web of Science for English-language publications from January 1, 1990, through December 10, 2024 (last search December 10, 2024). Predefined terms combined \u201cupper tract urothelial carcinoma\u201d or \u201cUTUC\u201d with \u201cskin,\u201d \u201ccutaneous,\u201d \u201cabdominal wall,\u201d or \u201cport-site,\u201d and with \u201cmetastasis,\u201d \u201cimplantation,\u201d or \u201cseeding.\u201d Inclusion criteria were human case reports or small series with histologically confirmed UTUC and cutaneous involvement. We excluded non-UTUC primaries, noncutaneous metastases, pure reviews without primary cases, duplicate reports, and articles lacking extractable case-level clinical or pathologic data. Two reviewers independently screened records and extracted data (patient and tumor features, site and timing of cutaneous involvement, other metastases, postdiagnosis treatment, and outcomes), resolving discrepancies by consensus. Owing to rarity and heterogeneity, we performed a qualitative descriptive synthesis without meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A patient developed a progressively enlarging cutaneous mass on the abdominal wall at a prior laparoscopic port site following renal cyst surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Biopsy confirmed metastatic poorly differentiated urothelial carcinoma. On April 27, 2023, the patient underwent robot-assisted radical nephrectomy with abdominal wall tumor resection and latissimus dorsi myocutaneous flap transfer. Postoperative pathology revealed high-grade urothelial carcinoma with human epidermal growth factor receptor 2 (+++) expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Gemcitabine\/cisplatin was administered initially; however, due to intolerance to cisplatin-based chemotherapy, sequential disitamab vedotin (120\u2009mg every 3 weeks) plus tislelizumab (200\u2009mg every 3 weeks) was initiated on November 23, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>At 24-month postoperative follow-up, there was no evidence of local recurrence at the surgical site.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Cutaneous metastasis in UTUC is rare and portends a poor prognosis. Radical surgery combined with systemic therapy remains the cornerstone of care. In this case, disitamab vedotin plus tislelizumab, used as a postoperative sequential systemic regimen, demonstrated favorable safety and achieved a 24-month recurrence-free interval after discontinuation of gemcitabine\/cisplatin due to intolerance, with manageable adverse effects. This combination may represent a potential treatment option for metastatic UTUC, although its efficacy requires validation in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046529","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:03:02Z","timestamp":1767988982000},"page":"e46529","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy sequential disitamab vedotin in combination with tislelizumab as systemic therapy of upper tract urothelial carcinoma with cutaneous metastasis: A case report and literature review"],"prefix":"10.1097","volume":"105","author":[{"given":"Kangyu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5513-1348","authenticated-orcid":false,"given":"Baixin","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260805","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 update.","volume":"84","author":"Roupr\u00eat","year":"2023","journal-title":"Eur Urol"},{"key":"R2-20260805","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","article-title":"Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC).","volume":"35","author":"Soria","year":"2017","journal-title":"World J Urol"},{"key":"R3-20260805","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.seminoncol.2016.02.027","article-title":"Cutaneous manifestations of genitourinary malignancy.","volume":"43","author":"Raghavan","year":"2016","journal-title":"Semin Oncol"},{"issue":"5 Pt 2","key":"R4-20260805","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0190-9622(00)90256-1","article-title":"A painful cutaneous nodule as the presentation of metastatic transitional cell carcinoma of the renal pelvis.","volume":"42","author":"Zirwas","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"R5-20260805","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bju.12238","article-title":"Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high-volume centre in China.","volume":"112","author":"Chen","year":"2013","journal-title":"BJU Int"},{"key":"R6-20260805","first-page":"525","article-title":"Transitional cell carcinoma metastasis to arm skin from the renal pelvis.","volume":"26","author":"Lin","year":"2003","journal-title":"Chang Gung Med J"},{"issue":"2 Pt 1","key":"R7-20260805","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0190-9622(08)81982-2","article-title":"Zosteriform inflammatory metastatic carcinoma from transitional cell carcinoma of the renal pelvis.","volume":"31","author":"Ando","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"R8-20260805","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/iju5.12350","article-title":"Cutaneous metastasis emerging during chemotherapy and progressing during immunotherapy for urothelial carcinoma.","volume":"4","author":"Otsuka","year":"2021","journal-title":"IJU Case Rep"},{"key":"R9-20260805","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/jjco\/hyab067","article-title":"Cutaneous metastasis of renal pelvic urothelial carcinoma mimicking cutaneous angiosarcoma.","volume":"51","author":"Endo","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"R10-20260805","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jnci.2017.11.001","article-title":"Cytological diagnosis of a rare case of cutaneous metastasis from transitional cell carcinoma, renal pelvis.","volume":"29","author":"Singh","year":"2017","journal-title":"J Egypt Natl Canc Inst"},{"key":"R11-20260805","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13256-019-1997-8","article-title":"Multiple cutaneous metastasis of synchronous urothelial carcinoma of the bladder and the renal pelvis: a case report.","volume":"13","author":"Ghalleb","year":"2019","journal-title":"J Med Case Rep"},{"key":"R12-20260805","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.urology.2014.10.015","article-title":"Cutaneous metastasis of micropapillary urothelial carcinoma.","volume":"85","author":"Truong","year":"2015","journal-title":"Urology"},{"key":"R13-20260805","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.radcr.2020.11.038","article-title":"Cutaneous metastatic seeding as a sequela of nephrostomy catheter placement.","volume":"16","author":"Mirchia","year":"2021","journal-title":"Radiol Case Rep"},{"key":"R14-20260805","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2407-4-90","article-title":"Penile metastasis from primary transitional cell carcinoma of the renal pelvis: first manifestation of systemic spread.","volume":"4","author":"Pomara","year":"2004","journal-title":"BMC Cancer"},{"key":"R15-20260805","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1464-410X.1954.tb04922.x","article-title":"Cutaneous metastases from tumours of the bladder, urethra, and penis.","volume":"26","author":"Scott","year":"1954","journal-title":"Br J Urol"},{"key":"R16-20260805","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.urology.2004.01.014","article-title":"Cutaneous metastases from genitourinary malignancies.","volume":"63","author":"Mueller","year":"2004","journal-title":"Urology"},{"key":"R17-20260805","doi-asserted-by":"crossref","first-page":"1216725","DOI":"10.3389\/fonc.2023.1216725","article-title":"Nodular cutaneous metastasis of the leg in advanced urothelial bladder carcinoma: a case report and systematic literature review.","volume":"13","author":"Izzo","year":"2023","journal-title":"Front Oncol"},{"issue":"3 Pt 2","key":"R18-20260805","first-page":"1047","article-title":"Implantation metastasis after laparoscopic biopsy of bladder cancer.","volume":"153","author":"Andersen","year":"1995","journal-title":"J Urol"},{"key":"R19-20260805","first-page":"1005","article-title":"Radical pyelectomy for metastatic urothelial carcinoma after neoadjuvant therapy with vedicetuzumab combined with tiralizumab:a case report (in Chinese).","volume":"48","author":"Zhou","year":"2023","journal-title":"J Chongqing Med Univ"},{"key":"R20-20260805","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ju.0000099823.60465.e6","article-title":"Is there a role for surgery in the management of metastatic urothelial cancer? The M.D. Anderson experience.","volume":"171","author":"Siefker-Radtke","year":"2004","journal-title":"J Urol"},{"key":"R21-20260805","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1464-410X.2010.09675.x","article-title":"Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973\u20132005.","volume":"107","author":"Raman","year":"2011","journal-title":"BJU Int"},{"key":"R22-20260805","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/j.clgc.2015.04.013","article-title":"Pulmonary metastasectomy could prolong overall survival in select cases of metastatic urinary tract cancer.","volume":"13","author":"Kim","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"R23-20260805","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.euo.2020.11.005","article-title":"Incidence and survival rates of contemporary patients with invasive upper tract urothelial carcinoma.","volume":"4","author":"Coll\u00e0 Ruvolo","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"R24-20260805","article-title":"Diagnosis and treatment guidelines for urological and andrological diseases in China (2022 Edition) (in Chinese).","year":"2022","journal-title":"People\u2019s Medical Publishing House"},{"key":"R25-20260805","first-page":"677","article-title":"Research development of postoperative adjuvant therapy for upper tract urothelial carcinoma (in Chinese).","volume":"13","author":"Rao","year":"2022","journal-title":"Chin J Oncol Prev Treat"},{"key":"R26-20260805","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10585-024-10296-0","article-title":"Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real\u2011world study from ARON\u20112 project.","volume":"41","author":"Rizzo","year":"2024","journal-title":"Clin Exp Metastasis"},{"key":"R27-20260805","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10585-025-10374-x","article-title":"Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real\u2011world data and validation from ARON\u20112 dataset.","volume":"42","author":"Rizzo","year":"2025","journal-title":"Clin Exp Metastasis"},{"key":"R28-20260805","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clnesp.2025.03.023","article-title":"Prognostic significance of the cachexia index (CXI) in patients with cancer: a systematic review and meta\u2011analysis.","volume":"68","author":"Bas","year":"2025","journal-title":"Clin Nutr ESPEN"},{"key":"R29-20260805","doi-asserted-by":"crossref","first-page":"28309","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION\u201107 systematic review and meta\u2011analysis.","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci Rep"},{"key":"R30-20260805","first-page":"485","article-title":"China expert consensus on diagnosis and treatment of upper tract urothelial carcinoma.","volume":"39","year":"2018","journal-title":"Chin J Urol"},{"key":"R31-20260805","first-page":"150","article-title":"Value evaluation of immune checkpoint inhibitors combined with other therapies in advanced\/metastatic urothelial carcinoma (in Chinese).","volume":"44","author":"Luo","year":"2024","journal-title":"Int J Urol Nephrol"},{"key":"R32-20260805","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/13543784.2025.2473695","article-title":"Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma.","volume":"34","author":"Santoni","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"R33-20260805","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer.","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"R34-20260805","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","article-title":"Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase Ib DS8201-A-U105 study.","volume":"30","author":"Hamilton","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R35-20260805","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1200\/JCO.2024.42.16_suppl.4568","article-title":"Preliminary efficacy and safety results from RC48-C017: a phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression.","volume":"42","author":"Xinan","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T17:02:47Z","timestamp":1785949367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046529","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"2025-07-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}